Elicera Therapeutics AB (ELIC) - Total Liabilities

Latest as of September 2025: Skr6.97 Million SEK ≈ $750.01K USD

Based on the latest financial reports, Elicera Therapeutics AB (ELIC) has total liabilities worth Skr6.97 Million SEK (≈ $750.01K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Elicera Therapeutics AB to track the company's year-over-year net asset growth rate.

Elicera Therapeutics AB - Total Liabilities Trend (2014–2024)

This chart illustrates how Elicera Therapeutics AB's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Elicera Therapeutics AB to measure how efficiently the company converts operating cash flow to free cash.

Elicera Therapeutics AB Competitors by Total Liabilities

The table below lists competitors of Elicera Therapeutics AB ranked by their total liabilities.

Company	Country	Total Liabilities
Putra Rajawali Kencana PT JK:PURA	Indonesia	Rp111.50 Billion
Tractial S.A. PA:ALTRA	France	€4.68 Million
PN Poong Nyun Co. Ltd KQ:024940	Korea	₩9.69 Billion
Vistry Group PLC LSE:VTY	UK	GBX3.05 Billion
Strategic Resources Inc V:SR	Canada	CA$38.45 Million
Tier One Silver Inc V:TSLV	Canada	CA$2.03 Million
DeepMarkit Corp V:MKT	Canada	CA$653.62K

Liability Composition Analysis (2014–2024)

This chart breaks down Elicera Therapeutics AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Elicera Therapeutics AB worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	5.35	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.23	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.19	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Elicera Therapeutics AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Elicera Therapeutics AB (2014–2024)

The table below shows the annual total liabilities of Elicera Therapeutics AB from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	Skr6.79 Million ≈ $730.97K	-50.70%
2023-12-31	Skr13.78 Million ≈ $1.48 Million	+2.00%
2022-12-31	Skr13.51 Million ≈ $1.45 Million	+440.31%
2021-12-31	Skr2.50 Million ≈ $269.05K	+6.22%
2020-12-31	Skr2.35 Million ≈ $253.30K	+58742.88%
2019-12-31	Skr4.00K ≈ $430.46	0.00%
2018-12-31	Skr4.00K ≈ $430.46	0.00%
2017-12-31	Skr4.00K ≈ $430.46	-96.79%
2016-12-31	Skr124.60K ≈ $13.41K	-66.03%
2015-12-31	Skr366.76K ≈ $39.47K	-38.55%
2014-12-31	Skr596.87K ≈ $64.23K	--

About Elicera Therapeutics AB

ST:ELIC Sweden Biotechnology

Market Cap

$12.17 Million

Skr113.09 Million SEK

Market Cap Rank

#26518 Global

#571 in Sweden

Share Price

Skr2.33

Change (1 day)

-2.51%

52-Week Range

Skr2.30 - Skr7.90

All Time High

Skr8.56